Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Phytopathology|March 11, 2026
Modelling Biological Responses to Meteorological Variables to Predict Disease Risk for European Canker (Neonectria ditissima) in AppleRebecca E Campbell, Robert M Beresford, Nicholas T Amponsah, et al.
Molecular Plant Pathology|January 5, 2011
Venturia inaequalis: the causal agent of apple scabJoanna K Bowen, Carl H Mesarich, Vincent G M Bus, et al.
Clinical Radiology|January 11, 2021
Radiological assessment of response and adverse events associated with novel systemic oncological therapiesS Veerasuri, D Little, K N De Paepe, et al.
Bioorganic & Medicinal Chemistry Letters|April 3, 2019
The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cellsKetan C Ruparelia, Sabahat Lodhi, Dyan N Ankrett, et al.
European Journal of Medicinal Chemistry|February 12, 2017
Synthesis and antitrypanosomal activities of novel pyridylchalconesAvninder S Bhambra, Ketan C Ruparelia, Hoon L Tan, et al.
Molecules (Basel, Switzerland)|January 23, 2024
CYP1-Activation and Anticancer Properties of Synthetic Methoxylated Resveratrol AnaloguesKetan C Ruparelia, Keti Zeka, Kenneth J M Beresford, et al.
British Journal of Cancer|May 17, 2014
Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancerD K Woolf, M Beresford, S P Li, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2017
(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agentNeill J Horley, Kenneth J M Beresford, Supriya Kaduskar, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|January 16, 2018
The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer CellsKetan C Ruparelia, Keti Zeka, Taeeba Ijaz, et al.
European Journal of Medicinal Chemistry|February 22, 2017
Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing linesNeill J Horley, Kenneth J M Beresford, Tarun Chawla, et al.
Pageof 4